SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that

REZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS,

REZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS,

JP Morgan analyst Jessica Fye reinstates Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and ann

Nektar Therapeutics maintains a Strong Buy rating, driven by REZPEG's late-stage development in atop

NKTR's Q2 earnings beat estimates, but revenues fall short. Investor focus stays on rezpeg as late-s

Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript

Nektar Therapeutics NASDAQ: NKTR said it initiated its global Phase III ZENITH AD program for rezpeg

Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.23 per share versus the Zacks Consen

Nektar Therapeutics (NASDAQ:NKTR) held its second-quarter earnings conference call on Thursday. Belo

SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage bi

NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves

Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) will likely be releasing its Q2 2026 results af

SAN FRANCISCO, July 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its fi

The average of price targets set by Wall Street analysts indicates a potential upside of 104.1% in N

Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) shares gapped up before the market opened on Fr

SAN FRANCISCO, July 24, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that

Nektar begins two phase III ZENITH AD studies of rezpeg for moderate-to-severe atopic dermatitis, wi

Canaccord Genuity analyst Edward Nash initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) wit

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Two global registrational Phase 3 trials initiated in ZENITH AD programPhase 3 program based upon cl

Two global registrational Phase 3 trials initiated in ZENITH AD program Phase 3 program based upon c

SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that

Robin sold 20,000 shares over two days for a transaction value of $1.22 million at a weighted averag

Big pharma's appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeu

SAN FRANCISCO, June 3, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that,

Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and lowers

On May 8, 2026, Nektar Therapeutics (the "Company") entered into an Equity Distribution Agre

Piper Sandler analyst Yasmeen Rahimi maintains Nektar Therapeutics (NASDAQ:NKTR) with a Overweigh

Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(1.82) per share which missed the an

Citigroup analyst Samantha Semenkow maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and ra

Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and raises

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the developmen

HC Wainwright & Co. analyst Arthur He maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy

BTIG analyst Julian Harrison maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises th

Nektar Therapeutics (NASDAQ: NKTR) rose on positive results for alopecia treatment. Other top gainer

Nektar Therapeutics shares are trading higher Monday after a blinded 16-week treatment extension res

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of

Rezpegaldesleukin demonstrates statistically significant improvement in mean percent EASI improvemen

Wedbush analyst Martin Fan initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Neutra

Rezpegaldesleukin is a novel first-in-class regulatory T (Treg) cell stimulator designed to address

Citigroup analyst Samantha Semenkow maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and ra

Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(1.78) per share which beat the anal

B. Riley Securities analyst Mayank Mamtani reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Bu

Nektar is selling 6,603,449 shares of common stock and 293,103 pre-funded warrants in the offering.

Nektar Therapeutics stock surged after positive data showed sustained and deepening disease control

 Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on the developmen

HC Wainwright & Co. analyst Arthur He maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy